对早产儿视网膜病变的抗血管内皮生长因子治疗的最新情况
M Hossein Nowroozzadeh1, Elham Sadeghi2, Hossein Shahriari-Garaee1
1Department of Ophthalmology, Shiraz University of Medical Sciences, Shiraz, Iran.
Journal of current ophthalmology
|January 22, 2024
概括
抗血管内皮生长因子 (抗VEGF) 治疗对早产视网膜病变 (ROP) 有效,但由于潜在的重新激活,需要保持警的随访. 需要进一步研究以优化其使用并评估长期安全性.
科学领域:
- 眼科医生 眼科 眼科
- 新生儿医学 新生儿医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 早产视网膜病变 (ROP) 是早产婴儿视力受损的主要原因.
- 抗血管内皮生长因子 (anti-VEGF) 药物已经成为一种重要的治疗选择.
研究的目的:
- 提供关于抗VEGF治疗早产视网膜病变的有效性和安全性的最新审查.
- 综合有关抗VEGF治疗方案和结果的当前证据.
主要方法:
- 在PubMed和Scopus数据库 (2005-2022) 中进行全面的文献搜索.
- 包含相关的已发表文章.
- 选择研究的分类,总结和批判分析.
主要成果:
- 抗VEGF药物在特定区域的类型1 ROP的初始治疗中表现出优于激光治疗的优势.
- 在使用抗VEGF单一治疗时,存在重激活或持续无血管视网膜的显著风险.
- 在抗VEGF治疗后,密切监测和潜在的辅助激光疗法至关重要.
结论:
- 抗VEGF治疗在管理早产视网膜病变方面发挥着不可或缺的作用.
- 进一步的研究是必不可少的,以完善指示,最佳剂量,并评估长期的眼睛和系统安全性.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
166
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
166
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K


